Batu Biologics Revenue and Competitors

Batu Biologics is a biotechnology-based pharmaceutical company focused on the development and commercialization of novel therapies that target the “Achilles Heel of Cancer”: the tumor blood vessels. Our lead product is a polyvalent therapeutic vaccine targeting the tumor endothelium, ValloVax™. Advantages of targeting the tumor endothelium directly: • Immune access: many tumor associated antigens are sequestered from the immune system, whereas the tumor endothelium is in direct contact with the immune system via blood. Furthermore many late stage tumors are highly heterogeneous and often do not have immunogeneic neo-angtigens or tumor associated antigens expressed • Collateral damage to the tumor: Dr. Folkman the pioneer of angiogenesis showed that for every 1 tumor endothelial cell killed, approximately 200-300 tumor cells die. • Reduction of tumor metastasis and invasiveness: ValloVax has been shown to reduce metastasis in a LLC spontaneous metastasis model. Furthermore, preventing the recurrence of tumor angiogenesis may have applications post-surgical resection